Why Monopar Therapeutics (MNPR) is Ideal for Trend Investing

When it comes to short-term investing or trading, the saying goes, "the trend is your friend." This approach is often seen as the most profitable strategy in the stock market. However, ensuring that a trend is sustainable enough to make a profit is not always straightforward.

Many investors find that trends can reverse before they exit a trade, leading to unexpected short-term capital losses. To achieve profitable trades, it is crucial to confirm factors such as solid fundamentals and positive earnings estimates that can uphold the stock's momentum.

To aid in identifying stocks with a strong upward trend, we have developed a "Recent Price Strength" screening tool. This unique short-term trading strategy facilitates the process of filtering stocks that possess enough fundamental strength to sustain their recent upward trajectory. Notably, it filters only those stocks that are trading closer to the upper range of their 52-week high and low, often signaling bullish behavior.

Among the stocks that successfully passed through this screening process is Monopar Therapeutics Inc. (MNPR). Here are several reasons why this stock stands out as a prime candidate for trend investing.

Remarkable Price Increase

Over a span of 12 weeks, Monopar Therapeutics has seen a staggering price increase of 842.7%. This considerable rise reflects investors' ongoing confidence in the stock, suggesting they are eager to pay more in anticipation of future growth.

However, merely observing a price increase over three months does not provide a complete picture. It's also essential to analyze more recent trends to ensure that there's no impending reversal. In the last four weeks alone, MNPR's stock price surged by 54%, indicating that the upward trend remains intact.

Positioning and Fundamentals

Currently, MNPR is trading at approximately 83% of its 52-week high-low range, suggesting that it may be on the cusp of a breakout. This positioning further supports the trend that investors are closely watching.

Regarding fundamentals, MNPR boasts a Zacks Rank of #2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on trends related to earnings estimates and earnings per share (EPS) surprises. These are critical components influencing a stock's short-term price movements.

The Zacks Rank system utilizes four essential factors concerning earnings estimates to categorize stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell). Historically, Zacks Rank #1 stocks have achieved an average annual return of +25% since 1988. Additionally, MNPR holds an impressive Average Broker Recommendation of #1 (Strong Buy), underscoring the positive sentiment around its near-term price performance.

Given these factors, it appears that the positive price trend for MNPR is unlikely to reverse shortly.

In addition to Monopar Therapeutics, several other stocks currently meet the criteria set out in our "Recent Price Strength" screen. Investors may want to explore these options to uncover promising stocks that showcase similar upward momentum.

Furthermore, this is not the only screening tool available to identify potentially lucrative stock picks. Depending on individual investing strategies, one can choose from over 45 Zacks Premium Screens, specifically designed to outperform market standards.

It's essential to remember that a successful stock-picking strategy is one that has produced positive results in the past. Tools like the Zacks Research Wizard enable investors to backtest the effectiveness of their strategies while also providing a wealth of successful stock-picking methodologies.

Click here to sign up for a free trial of the Research Wizard today.

Investing, Stocks, Trading